Restatement Radar
Numbers that companies quietly changed after they first reported them — each one diffed across two SEC filings, both linked.
38,379 revisions on filemost recent 2026-08-21
BLISNAPC Defense, Inc.
7th largest revision in BLIS's history
Stockholders' Equity Attributable to Parent·As of Apr 30, 2024
Notable restatement$769.3K▲ 7.6%was$714.7K
Revised up in a 10-K/A.
Amended filingLRHCLa Rosa Holdings Corp.
9th largest revision in LRHC's history
Revenue from Contract with Customer, Including Assessed Tax·Q2 2025
Major restatement$20.2M▼ 12.8%was$23.2M
Revised down in a 10-Q. Any P/S built on the original was 14.7% too low.
Non-reliance noticeVTIXVirtuix Holdings Inc.
2nd largest revision in VTIX's history
Liabilities·As of Mar 31, 2026
Major restatement$13.7M▲ 16.7%was$11.7M
Revised up in a 10-Q/A.
Amended filingBGMSBio Green Med Solution, Inc.
8th largest revision in BGMS's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2025
Notable restatement-$1.2M▲ 5.2%was-$1.3M
Revised up.
No amendment filedVTIXVirtuix Holdings Inc.
Information Technology
Stockholders' Equity Attributable to Parent·As of Mar 31, 2026
Major restatement$1.1M▼ 64.0%was$3M
Revised down in a 10-Q/A.
Amended filingBGMSBio Green Med Solution, Inc.
9th largest revision in BGMS's history
Operating Income (Loss)·Q2 2025
Notable restatement-$1.2M▲ 5.2%was-$1.3M
Revised up.
No amendment filedCNSPCNS Pharmaceuticals, Inc.
2nd largest revision in CNSP's history
Net Income (Loss) Attributable to Parent·FY 2024
Major restatement-$14.9K▲ 99.9%was-$14.9M
Revised up.
No amendment filedCNSPCNS Pharmaceuticals, Inc.
Health Care
Net Income (Loss) Attributable to Parent·FY 2023
Major restatement-$18.9K▲ 99.9%was-$18.9M
Revised up.
No amendment filedCNSPCNS Pharmaceuticals, Inc.
3rd largest revision in CNSP's history
Net Income (Loss) Attributable to Parent·FY 2025
Major restatement-$16K▲ 99.9%was-$15.9M
Revised up.
No amendment filedVTIXVirtuix Holdings Inc.
3rd largest revision in VTIX's history
Liabilities, Current·As of Mar 31, 2026
Major restatement$10.7M▲ 22.3%was$8.8M
Revised up in a 10-Q/A.
Amended filingIQSTiQSTEL Inc
6th largest revision in IQST's history
Stockholders' Equity Attributable to Parent·As of Dec 31, 2024
Major restatement$11.9M▲ 64.9%was$7.2M
Revised up in a 10-Q/A.
Amended filingNIVFNewGenIvf Group Ltd
5th largest revision in NIVF's history
Comprehensive Income (Loss), Net of Tax, Attributable to Parent·FY 2023
Major restatement$85.7K▼ 24.4%was$113.3K
Revised down.
No amendment filedRRRICHTECH ROBOTICS INC.
5th largest revision in RR's history
Liabilities·As of Sep 30, 2025
Major restatement$22.2M▲ 659.3%was$2.9M
Revised up in a 10-Q.
Non-reliance noticeRMTGRegenerative Medical Technology Group Inc.
Consumer Staples
Net Income (Loss) Attributable to Parent·Q2 2025
Major restatement-$1.4M▼ 10.6%was-$1.3M
Revised down in a 10-Q.
No amendment filedRMTGRegenerative Medical Technology Group Inc.
3rd largest revision in RMTG's history
Stockholders' Equity Attributable to Parent·As of Dec 31, 2025
Notable restatement-$36M▼ 3.8%was-$34.7M
Revised down in a 10-Q.
No amendment filedRMTGRegenerative Medical Technology Group Inc.
8th largest revision in RMTG's history
Stockholders' Equity Attributable to Parent·As of Mar 31, 2026
Notable restatement-$36.4M▼ 2.1%was-$35.6M
Revised down in a 10-Q.
No amendment filedRMTGRegenerative Medical Technology Group Inc.
6th largest revision in RMTG's history
Liabilities·As of Dec 31, 2025
Notable restatement$40.5M▲ 3.3%was$39.2M
Revised up in a 10-Q.
No amendment filedOPTTOcean Power Technologies, Inc.
Utilities
Net Income (Loss) Attributable to Parent·FY 2025
Major restatement-$24.5M▼ 13.7%was-$21.5M
Revised down in a 10-K.
No amendment filedOPTTOcean Power Technologies, Inc.
2nd largest revision in OPTT's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2025
Major restatement-$25.5M▼ 13.1%was-$22.5M
Revised down in a 10-K.
No amendment filedBKVBKV Corp
Energy
Liabilities·As of Dec 31, 2024
Major restatement$1.5B▲ 130.3%was$671.5M
Revised up in a 10-K/A.
Amended filingBKVBKV Corp
6th largest revision in BKV's history
Operating Income (Loss)·FY 2025
Major restatement$303.7M▲ 39.6%was$217.6M
Revised up in a 10-K/A.
Amended filingBKVBKV Corp
3rd largest revision in BKV's history
Liabilities·As of Dec 31, 2025
Major restatement$1.9B▲ 75.1%was$1.1B
Revised up in a 10-K/A.
Amended filingBKVBKV Corp
2nd largest revision in BKV's history
Net Cash Provided by (Used in) Operating Activities·FY 2023
Major restatement$260.3M▲ 111.5%was$123.1M
Revised up in a 10-K/A. Any P/OCF built on the original was 52.7% too high.
Amended filingBKVBKV Corp
5th largest revision in BKV's history
Operating Income (Loss)·FY 2023
Major restatement$241.1M▲ 53.0%was$157.6M
Revised up in a 10-K/A.
Amended filingBKVBKV Corp
7th largest revision in BKV's history
Assets·As of Dec 31, 2024
Major restatement$3.1B▲ 38.9%was$2.2B
Revised up in a 10-K/A.
Amended filingBKVBKV Corp
4th largest revision in BKV's history
Operating Income (Loss)·FY 2024
Major restatement-$64.2M▲ 58.5%was-$154.8M
Revised up in a 10-K/A.
Amended filingBKVBKV Corp
10th largest revision in BKV's history
Revenue from Contract with Customer, Excluding Assessed Tax·FY 2023
Major restatement$1B▲ 36.6%was$739.3M
Revised up in a 10-K/A. Any P/S built on the original was 26.8% too high.
Amended filingSLSNSOLESENCE, INC.
Health Care
Net Income (Loss) Attributable to Parent·Q2 2025
Major restatement$343K▲ 328.8%was$80K
Revised up in a 10-Q. Any P/E built on the original was 76.7% too high.
Non-reliance noticeSLSNSOLESENCE, INC.
8th largest revision in SLSN's history
Stockholders' Equity Attributable to Parent·As of Mar 31, 2025
Major restatement$10.8M▼ 28.6%was$15.2M
Revised down in a 10-Q.
Non-reliance noticeSLSNSOLESENCE, INC.
9th largest revision in SLSN's history
Net Income (Loss) Attributable to Parent·Q2 2026
Major restatement-$962K▼ 25.6%was-$766K
Revised down in a 10-Q.
Non-reliance noticeSLSNSOLESENCE, INC.
10th largest revision in SLSN's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2026
Major restatement-$962K▼ 25.6%was-$766K
Revised down in a 10-Q.
Non-reliance noticeSLSNSOLESENCE, INC.
7th largest revision in SLSN's history
Operating Income (Loss)·Q2 2025
Major restatement$2.5M▲ 29.6%was$1.9M
Revised up in a 10-Q.
Non-reliance noticeSLSNSOLESENCE, INC.
4th largest revision in SLSN's history
Operating Income (Loss)·Q2 2026
Major restatement-$700K▼ 38.9%was-$504K
Revised down in a 10-Q.
Non-reliance noticeSLSNSOLESENCE, INC.
5th largest revision in SLSN's history
Stockholders' Equity Attributable to Parent·As of Dec 31, 2024
Major restatement$10.4M▼ 30.7%was$14.9M
Revised down in a 10-Q.
Non-reliance noticeBGFRBestGofer Inc.
7th largest revision in BGFR's history
Assets, Current·As of Nov 30, 2025
Major restatement$37.7K▲ 49.6%was$25.2K
Revised up in a 10-Q.
Non-reliance noticeSONMDNA X, Inc.
4th largest revision in SONM's history
Operating Income (Loss)·Q2 2025
Major restatement-$1.5M▲ 78.1%was-$6.7M
Revised up in a 10-Q.
No amendment filedSONMDNA X, Inc.
5th largest revision in SONM's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2025
Major restatement-$1.9M▲ 74.6%was-$7.3M
Revised up in a 10-Q.
No amendment filedSBEVSPLASH BEVERAGE GROUP, INC.
10th largest revision in SBEV's history
Revenues·Q2 2025
Major restatement$45.2K▼ 89.7%was$438.3K
Revised down in a 10-Q. Any P/S built on the original was 869.6% too low.
No amendment filedPTIXProtagenic Therapeutics, Inc.\new
6th largest revision in PTIX's history
Net Cash Provided by (Used in) Operating Activities·Q1 2025
Major restatement-$1.8M▼ 50.0%was-$1.2M
Revised down in a 10-Q.
No amendment filedPTIXProtagenic Therapeutics, Inc.\new
7th largest revision in PTIX's history
Operating Income (Loss)·Q1 2025
Major restatement-$1.2M▲ 48.5%was-$2.3M
Revised up in a 10-Q.
No amendment filed